Associations between SOX2 and miR-200b expression with the clinicopathological characteristics and prognosis of patients with glioma

Wang, Bin; Li, Ming; Wu, Zhonghua; Li, Xiqing; Li, Y U; Shi, Xiaohong; Cheng, Wenlan

doi:10.3892/etm.2015.2488

Cited by 16 publications

(12 citation statements)

References 45 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to previous studies [ 10 , 13 , 28 , 67 , 68 , 77 , 78 ], co-staining for SOX2, CD133 and Nestin across a single section also provided a few unexpected observations. In particular, the average number of cells positive for both SOX2 and CD133 was lower in grade II/III meningiomas, while cells positive for SOX2 and negative CD133 increased in frequency.…”

Section: Discussionmentioning

confidence: 55%

In situ characterization of stem cells-like biomarkers in meningiomas

et al. 2018

View full text Add to dashboard Cite

BackgroundMeningioma cancer stem cells (MCSCs) contribute to tumor aggressiveness and drug resistance. Successful therapies developed for inoperable, recurrent, or metastatic tumors must target these cells and restrict their contribution to tumor progression. Unfortunately, the identity of MCSCs remains elusive, and MSCSs’ in situ spatial distribution, heterogeneity, and relationship with tumor grade, remain unclear.MethodsSeven tumors classified as grade II or grade III, including one case of metastatic grade III, and eight grade I meningioma tumors, were analyzed for combinations of ten stem cell (SC)-related markers using immunofluorescence of consecutive sections. The correlation of expression for all markers were investigated. Three dimensional spatial distribution of markers were qualitatively analyzed using a grid, designed as a repository of information for positive staining. All statistical analyses were completed using Statistical Analysis Software Package.ResultsThe patterns of expression for SC-related markers were determined in the context of two dimensional distribution and cellular features. All markers could be detected in all tumors, however, Frizzled 9 and GFAP had differential expression in grade II/III compared with grade I meningioma tissues. Correlation analysis showed significant relationships between the expression of GFAP and CD133 as well as SSEA4 and Vimentin. Data from three dimensional analysis showed a complex distribution of SC markers, with increased gene hetero-expression being associated with grade II/III tumors. Sub regions that showed multiple co-staining of markers including CD133, Frizzled 9, GFAP, Vimentin, and SSEA4, but not necessarily the proliferation marker Ki67, were highly associated with grade II/III meningiomas.ConclusionThe distribution and level of expression of CSCs markers in meningiomas are variable and show hetero-expression patterns that have a complex spatial nature, particularly in grade II/III meningiomas. Thus, results strongly support the notion of heterogeneous populations of CSCs, even in grade I meningiomas, and call for the use of multiple markers for the accurate identification of individual CSC subgroups. Such identification will lead to practical clinical diagnostic protocols that can quantitate CSCs, predict tumor recurrence, assist in guiding treatment selection for inoperable tumors, and improve follow up of therapy.Electronic supplementary materialThe online version of this article (10.1186/s12935-018-0571-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 55%

In situ characterization of stem cells-like biomarkers in meningiomas

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Sathyan et al found that glioblastoma patients with low miR-21/high SOX2 expression had longer overall survival than those with high miR-21/low SOX2 (15.3 vs. 16.7 months, p = 0.0088), which was in accordance with our results. While Wang et al reported that expression of SOX2 predicted poor prognosis (22). Twenty four HGG cases with both primary tumor samples and recurrent samples were analyzed in the present study.…”

Section: Discussionmentioning

confidence: 98%

Glioma SOX2 expression decreased after adjuvant therapy

Ren

et al. 2019

Preprint

View full text Add to dashboard Cite

Objectives: SOX2 is regarded as an important marker in stem cell. The change of SOX2 expression after adjuvant therapy in high grade glioma (HGG) remains unknown so far. Few patients with recurrent glioma have opportunity to undergo operation once again, so the recurrent glioma samples are scarce. This study tries to analyze SOX2 expression in paired primary and recurrent HGG, aims to better understand the transformation law of SOX2 after adjuvant therapy in HGG. Methods: Twenty-four recurrent HGG patients who undergone a second resection were included. 16 patients received adjuvant therapy, the remaining 8 patients didn’t receive any adjuvant therapy at all. The protein expression of SOX2 in paired primary and recurrent HGG was tested by immunohistochemistry. The statistical analysis was conducted by IBM SPSS Statistics 19.0. Results: In primary HGG, SOX2 expression of 3+,2+,1+ and 0+ were seen in 20 (83.3%), 1 (4.2%), 1 (4.2%) and 2 cases (8.3%), respectively. The expression of SOX2 was decreased in recurrent HGG compared to the paired primary sample (p=0.001). The decrease of SOX2 was often seen in patients received chemotherapy, radiotherapy or both (p=0.003). Patients with SOX2 high expression in primary glioma had a longer median PFS than those with SOX2 low expression with marginal statistic significance (12.7 vs. 5.4 months, p=0.083). For cases with SOX2 high expression in the primary glioma, those had SOX2 low expression after recurrence seemed to have worse prognosis as compared to patients with stable SOX2 high expression (PFS: 10.4 vs. 14.9 months, p=0.036; OS: 27.0 vs 49.5 months, p=0.005). Conclusions: This is the first study comparing the protein expression of SOX2 in recurrent HGG and its paired primary tumor. SOX2 high expression is common in brain HGG, a tendency of decreased SOX2 expression in recurrent gliomas was evidenced. Lower SOX2 expression was seen in those patients received adjuvant chemotherapy and/or radiotherapy. Patients with low SOX2 expression in primary HGG usually have poorer prognosis, those with SOX2 expression decreased in recurrent HGG had worse outcome.

show abstract

“…Sathyan et al found that glioblastoma patients with low miR-21/high SOX2 expression had longer overall survival than those with high miR-21/low SOX2 (15.3 vs. 16.7 months, p=0.0088), which was in accordance with our results. While Wang et al reported that expression of SOX2 predicted poor prognosis (22). It has been reported that expression of SOX2 related to promoter methylation (23) (24)(25)(26)(27)(28)(29).…”

Section: Discussionmentioning

confidence: 99%

Glioma SOX2 expression decreased after adjuvant therapy

Ren

et al. 2019

Preprint

View full text Add to dashboard Cite

SOX2 is regarded as an important marker in stem cell. The change of SOX2 expression after adjuvant therapy in high grade glioma (HGG) remains unknown so far. Few patients with recurrent glioma have opportunity to undergo operation once again, so the recurrent glioma samples are scarce. This study tries to analyze SOX2 expression in paired primary and recurrent HGG, aims to better understand the transformation law of SOX2 after adjuvant therapy in HGG.Methods Twenty-four recurrent HGG patients who undergone a second resection were included. 16 patients received adjuvant therapy, the remaining 8 patients didn’t receive any adjuvant therapy at all. The protein expression of SOX2 in paired primary and recurrent HGG was tested by immunohistochemistry. The statistical analysis was conducted by IBM SPSS Statistics 19.0.Results In primary HGG, SOX2 expression of 3+,2+,1+ and 0+ were seen in 20 (83.3%), 1 (4.2%), 1 (4.2%) and 2 cases (8.3%), respectively. The expression of SOX2 was decreased in recurrent HGG compared to the paired primary sample (p=0.001). The decrease of SOX2 was often seen in patients received chemotherapy, radiotherapy or both (p=0.003). Patients with SOX2 high expression in primary glioma had a longer median PFS than those with SOX2 low expression with marginal statistic significance (12.7 vs. 5.4 months, p=0.083). For cases with SOX2 high expression in the primary glioma, those had SOX2 low expression after recurrence seemed to have worse prognosis as compared to patients with stable SOX2 high expression (PFS: 10.4 vs. 14.9 months, p=0.036; OS: 27.0 vs 49.5 months, p=0.005).Conclusions This is the first study comparing the protein expression of SOX2 in recurrent HGG and its paired primary tumor. SOX2 high expression is common in brain HGG, a tendency of decreased SOX2 expression in recurrent gliomas was evidenced. Lower SOX2 expression was seen in those patients who received adjuvant chemotherapy and/or radiotherapy. Patients with low SOX2 expression in primary HGG usually have poorer prognosis, those with SOX2 expression decreased in recurrent HGG had worse outcome.

show abstract

Associations between SOX2 and miR-200b expression with the clinicopathological characteristics and prognosis of patients with glioma

Cited by 16 publications

References 45 publications

In situ characterization of stem cells-like biomarkers in meningiomas

In situ characterization of stem cells-like biomarkers in meningiomas

Glioma SOX2 expression decreased after adjuvant therapy

Glioma SOX2 expression decreased after adjuvant therapy

Contact Info

Product

Resources

About